AI Deal Activity Remains Strong in Healthcare Amid Decline in Fundraising; Silicon Valley Bank Releases 16th Edition of Healthcare Investments and Exits Report

Rhea-AI Summary

Silicon Valley Bank (FCNCA), a division of First Citizens Bank, has released its 16th Healthcare Investments and Exits Report, highlighting strong AI deal activity in healthcare despite overall fundraising decline. AI-related healthtech deals doubled in the past 12 months, while non-AI companies saw a 20% decrease over three years.

Key findings show that healthtech accounted for 33% of total healthcare investment, with AI healthtech representing 21%. Back-office AI applications dominated with 44% of all AI investment in H1 2025. In China, biopharma licensing deals reached $3 billion in H1 2025, surpassing 2024 levels. The report also reveals that healthtech raised $8.2 billion in H1 2025, marking the strongest half since H1 2022.

Positive

• None.

Negative

• Overall healthcare fundraising tracking for lowest amount in over a decade
• Non-AI companies experienced 20% decrease in deal activity over three years
• Diagnostics and tools deal activity has slowed since 2024
• Potential negative impact of tariffs on medical device companies

News Market Reaction – FCNCA

-0.88%

-0.88% Session move

In the trading session that priced this news, FCNCA declined 0.88%, reflecting a mild negative market reaction.

Data tracked by StockTitan Argus on the day of publication.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

AI and back-office software driving growth; China biopharma licensing on track for record year

SAN FRANCISCO, July 29, 2025 /PRNewswire/ -- Despite a decline in overall fundraising, which is on track for the lowest amount closed in more than a decade, AI-related deal activity remains a bright spot for the healthcare sector, according to the latest report from Silicon Valley Bank (SVB), a division of First Citizens Bank. Over the last three years, all healthcare sectors saw strong growth in AI deal activity while companies not leveraging AI saw a 20% decrease.

"Despite a challenging fundraising environment, we continue to see encouraging signals across the market – particularly in AI investment across all sectors," said Jackie Spencer, Head of Relationship Management for Life Science and Healthcare Banking at Silicon Valley Bank and author of the annual Healthcare Investments and Exits Mid -Year Report. "Healthtech is leading the way, with AI-related deals doubling over the past 12 months. New AI applications are helping to reduce administrative burdens and drive greater efficiency throughout the healthcare system."

Silicon Valley Bank's mid-year 2025 Healthcare Investments and Exits report analyzes and predicts trends for venture capital investing, fundraising, and exits across healthtech, biopharma, diagnostics/tools (dx/tools), and device sectors in the US. The latest edition of the report also includes a spotlight on China.

China has established itself as a force in global biotech, with structural advantages in cost, development speed, and regulatory efficiency, according to the report. In the first half of 2025, total spending on Chinese biopharma licensing deals reached $3 billion, already more than what was spent in 2024.

Key Findings

AI Spotlight:

• Healthtech stands out: Despite headwinds in the overall market, investors are still spending on healthtech which accounted for about a third of total healthcare investment, with Healthtech AI accounting for 21%.
• AI tools attract funding: Mid-way through the year, half of all dollars going to dx/tools companies are going to those that leverage AI.
• Admin tops clinical spend: Back-office applications are taking center stage as AI adoption is focused on reducing administrative burden rather than clinic tasks—accounting for 44% of all AI investment in the first half of 2025.

Investment by Sector:

• Biopharma: Late-stage companies show favor; median biopharma pre-money valuations among Series C+ sat at $247M in H1 2025, compared to $46M and $87M for Series A and B biopharma startups, respectively.
• Healthtech: Healthtech remains strong as the sector raised $8.2 B total dollars during this half, the strongest half since H1 2022. Series B deal size jumped to $40M, the highest over the past five years.
• Dx/Tools: There are silver linings in a slowing market for early-stage diagnostics and tools companies. While deal activity has slowed since 2024, Series A median pre-money valuations and deal sizes hit a five-year high at $38M and $14M.
• Medical Device: Device investment proves to be consistent, totaling between $3B and $4B every half since 2022. However, macroeconomic events could cause a veer off course as device companies appear likely to be most impacted by tariffs.

Learn More
For a preview of the 2025 Healthcare Investments and Exits report, please visit: Healthcare Investments and Exits Report | Silicon Valley Bank

To share its deep industry knowledge, Silicon Valley Bank develops various insights reports focused on sectors spanning the innovation economy. For the complete library of Silicon Valley Bank's signature research reports, please visit Market Research Industry Trends & Insights | Silicon Valley Bank (svb.com) 

About Silicon Valley Bank
Silicon Valley Bank (SVB), a division of First Citizens Bank, is the bank of some of the world's most innovative companies and investors. SVB provides commercial banking to companies in the technology, life science and healthcare, private equity and venture capital industries. SVB operates in centers of innovation throughout the United States, serving the unique needs of its dynamic clients with deep sector expertise, insights and connections. SVB's parent company, First Citizens BancShares, Inc. (NASDAQ: FCNCA), is a top 20 U.S. financial institution with more than $200 billion in assets. First Citizens Bank, Member FDIC. Learn more at svb.com

 

View original content to download multimedia:https://www.prnewswire.com/news-releases/ai-deal-activity-remains-strong-in-healthcare-amid-decline-in-fundraising-silicon-valley-bank-releases-16th-edition-of-healthcare-investments-and-exits-report-302515867.html

SOURCE Silicon Valley Bank

FAQ

What are the key findings of Silicon Valley Bank's 2025 Healthcare Investments Report for AI investments?

The report shows that AI-related healthtech deals doubled in the past 12 months, with back-office applications accounting for 44% of all AI investment in H1 2025. Healthtech AI represented 21% of total healthcare investment.

How much did healthtech sector raise in H1 2025 according to Silicon Valley Bank?

Healthtech raised $8.2 billion in H1 2025, marking the strongest half since H1 2022, with Series B deal size reaching a five-year high of $40 million.

What is the state of biopharma investments in China for 2025?

Chinese biopharma licensing deals reached $3 billion in the first half of 2025, already surpassing the total spending for 2024, with advantages in cost, development speed, and regulatory efficiency.

What are the median pre-money valuations for biopharma companies in H1 2025?

Biopharma median pre-money valuations were $247M for Series C+, $87M for Series B, and $46M for Series A companies.

How has medical device investment performed since 2022?

Medical device investment has remained consistent, totaling between $3-4 billion every half since 2022, though potential tariffs may impact future performance.